Comparison between galectin-3 and YKL-40 levels for the assessment of liver fibrosis in cirrhotic patients.

[1]  Xiaoren Zhang,et al.  Chitinase-3 like-protein-1 function and its role in diseases , 2020, Signal Transduction and Targeted Therapy.

[2]  P. Bedossa,et al.  A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. , 2020, The lancet. Gastroenterology & hepatology.

[3]  Jian-hua Hu,et al.  Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. , 2020, Hepatobiliary & pancreatic diseases international : HBPD INT.

[4]  S. Zeuzem,et al.  Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis , 2020, Journal of clinical medicine.

[5]  C. Trautwein,et al.  Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis , 2020, Frontiers in Immunology.

[6]  Tabinda Hussain,et al.  Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography , 2019, European journal of gastroenterology & hepatology.

[7]  Ricardo Henao,et al.  Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease , 2018, Hepatology communications.

[8]  Hui Liu,et al.  Effects of dexmedetomidine on perioperative stress response, inflammation and immune function in patients with different degrees of liver cirrhosis , 2018, Experimental and therapeutic medicine.

[9]  M. Pirisi,et al.  Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review , 2018, Journal of clinical and translational hepatology.

[10]  Jun Cheng,et al.  Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT , 2018, Infection.

[11]  S. Qiu,et al.  Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis , 2017, Journal of Cancer.

[12]  C. Buechler,et al.  Adipokines in Liver Cirrhosis , 2017, International journal of molecular sciences.

[13]  H. Omar,et al.  APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: Systematic review and meta-analysis. , 2017, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[14]  R. Schwabe,et al.  Hepatocellular Carcinomas Originate Predominantly from Hepatocytes and Benign Lesions from Hepatic Progenitor Cells , 2017, Cell reports.

[15]  S. Lydersen,et al.  Risk factors of admission for acute colonic diverticulitis in a population-based cohort study: The North Trondelag Health Study, Norway , 2016, World journal of gastroenterology.

[16]  K. Chayama,et al.  Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease , 2016, Scientific Reports.

[17]  X. Qi,et al.  Child–Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis , 2016, Medicine.

[18]  A. Teixeira-Carvalho,et al.  Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10 , 2016, BMC Microbiology.

[19]  R. Flisiak,et al.  Galectin-3 Concentration in Liver Diseases. , 2015, Annals of clinical and laboratory science.

[20]  Yaojun Zhang,et al.  Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma , 2014, Journal of Translational Medicine.

[21]  Cheng Huang,et al.  The significance of YKL-40 protein in liver fibrosis , 2014, Inflammation Research.

[22]  Wen-bin Liu,et al.  The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[23]  Li-li Chen,et al.  Elevated Serum YKL-40 Level Predicts Poor Prognosis in Hepatocellular Carcinoma After Surgery , 2012, Annals of surgical oncology.

[24]  Y. Takada,et al.  Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[25]  C. Hellerbrand,et al.  Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. , 2011, Cytokine.

[26]  R. Shao,et al.  Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma* , 2011, The Journal of Biological Chemistry.

[27]  J. Medina-Pestana,et al.  YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection , 2010, Scandinavian journal of gastroenterology.

[28]  S. Hamdy,et al.  Non-invasive fibrosis seromarkers as a predictor of liver fibrosis in chronic hepatitis C and/or non-alcoholic steatohepatitis. , 2009, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[29]  J. Iredale,et al.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[31]  G. Bozkaya,et al.  Prognostic Significance of Serum Galectin-3 Levels in Patients with Hepatocellular Cancer and Chronic Viral Hepatitis , 2015, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[32]  R. Wiesner,et al.  Model for end-stage liver disease (MELD) and allocation of donor livers. , 2003, Gastroenterology.